食管切除术与根治性放化疗在食管癌患者中的比较
本研究基于台湾癌症登记库2008至2014年数据,比较临床I、II、III期食管鳞状细胞癌患者接受根治性放化疗(CRT)或单纯食管切除术的生存差异。共纳入5,487例患者,其中4,251例(77.50%)接受根治性CRT,1,236例(22.50%)接受单纯食管切除术。倾向匹配后1,020例配对比较显示,单纯食管切除术在临床I/II期患者中总生存显著优于根治性CRT,而临床III期患者两种治疗总生存相似。
要点
- 临床I/II期食管鳞癌,单纯食管切除术总生存优于根治性放化疗。
- 临床III期食管鳞癌,根治性放化疗与单纯食管切除术总生存相似。
- 治疗策略是多变量分析中的独立预后因素。
核心结论
- 对于临床I/II期食管鳞状细胞癌,单纯食管切除术比根治性放化疗提供更好的总生存。
- 对于临床III期食管鳞状细胞癌,根治性放化疗与单纯食管切除术的总生存率相似。
研究设计与样本
- 研究基于台湾癌症登记库2008至2014年数据,纳入5,487例临床I、II或III期食管鳞状细胞癌患者,接受根治性放化疗或单纯食管切除术。
- 采用倾向匹配分析,并进行单因素和多因素分析,按临床分期分层比较总生存。
主要发现
- 根治性放化疗组4,251例(77.50%),单纯食管切除术组1,236例(22.50%)。
- 倾向匹配后1,020例患者用于比较。
- 倾向匹配患者中,根治性放化疗组1年、2年、3年总生存率分别为60.92%、34.96%、26.14%;单纯食管切除术组分别为71.15%、56.50%、46.17%(p < 0.001)。
- 多因素分析显示治疗策略是独立预后因素。
- 临床I/II期患者中,单纯食管切除术与显著更好的总生存相关;临床III期患者中,根治性放化疗与单纯食管切除术无生存风险差异。
关键数值与推荐
- 倾向匹配后根治性放化疗组1年、2年、3年总生存率分别为60.92%、34.96%、26.14%。
- 倾向匹配后单纯食管切除术组1年、2年、3年总生存率分别为71.15%、56.50%、46.17%(p < 0.001)。
临床怎么用
- 临床I/II期食管鳞状细胞癌患者可优先考虑单纯食管切除术以改善生存。
- 临床III期食管鳞状细胞癌患者选择根治性放化疗或单纯食管切除术时,总生存相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study compared survival between definitive chemoradiotherapy (CRT) and esophagectomy alone among patients with locoregional esophageal squamous cell carcinoma (SCC). METHODS: Data were obtained from the Taiwan Cancer Registry between 2008 and 2014. Included were 5,487 patients with clinical I, II, or III esophageal SCC who received definitive CRT or esophagectomy alone. Patients were stratified according to clinical stage. Overall survival was compared between patients treated with definitive CRT versus esophagectomy alone, and between patients in the three different clinical stages. Propensity-matched analysis along with univariate and multivariate analysis were performed. RESULTS: Treatment was with definitive CRT in 4,251 patients (77.50%) and esophagectomy alone in 1,236 (22.50%). Propensity score matching produced 1,020 patients for comparison. The overall survival rates at 1, 2, and 3 years were 60.92%, 34.96%, and 26.14%, respectively, for propensity-matched patients treated with definitive CRT and were 71.15%, 56.50%, and 46.17%, respectively, for propensity-matched patients treated with esophagectomy alone (p < 0.001). Multivariate analysis showed treatment strategy was an independent prognostic factor. Esophagectomy alone was associated with significantly better overall survival than definitive CRT for patients with clinical stage I/II disease. There was no survival risk difference between definitive CRT and esophagectomy only for patients with clinical stage III disease. CONCLUSIONS: Esophagectomy alone could provide better survival than definitive CRT for patients with clinical stage I/II esophageal SCC. However, definitive CRT and esophagectomy yield similar overall survival rates in clinical stage III patients.
引用
- Wang BY, Hung WH, Wu SC, et al. Comparison Between Esophagectomy and Definitive Chemoradiotherapy in Patients With Esophageal Cancer. Ann Thorac Surg. 2018. PMID: 30571951. doi:10.1016/j.athoracsur.2018.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。